Last results 21 Jul 2026
Danaher Corporation
I · AI Analysis
The brief
Danaher manufactures specialized equipment and supplies that pharmaceutical companies use to develop and produce drugs, particularly biologics like monoclonal antibodies. They also make diagnostic instruments for hospitals and research labs, along with software and consumables that support the entire drug development lifecycle. The company serves customers in over 60 countries through well-known brands like Beckman Coulter, Leica Microsystems, and Pall.
Danaher is a $118 billion healthcare and life sciences conglomerate that makes equipment, chemicals, and software used by pharmaceutical companies and hospitals [Yahoo Finance]. The company operates through three divisions: Biotechnology (equipment for drug manufacturing), Life Sciences (research instruments and genomics tools), and Diagnostics (hospital testing equipment) [Yahoo Finance]. Despite recent stock underperformance, its core bioprocessing business is recovering strongly with equipment orders up 30%+ as pharma companies expand production capacity [Yahoo Finance].
Solid cash generation with moderate leverage, though profitability metrics show room for improvement
Sentinellis health
6.3/10
Moderate concerns
Market capitalisation
$118.2B
Revenue (TTM)
$24.6B
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadII · Recent news
What moved
6 stories · ranked by relevance
- Macro2026-05-20
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
Yahoo Finance
- Macro2026-05-20
Why The Narrative Around Danaher (DHR) Is Shifting With Bioprocess Recovery And Masimo Deal
Simply Wall St
- Macro2026-05-19
Genedata Introduces AI-Native CMC Platform to Accelerate Drug Development and Manufacturing
Yahoo Finance
- Macro2026-05-18
Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading
Yahoo Finance
- Macro2026-05-18
Japan In Vitro Diagnostics Market Research Trends and Forecast Report 2026-2035 Featuring, Abbott Laboratories, Arkray, Danaher, Fujirebio, H.U., Roche Diagnostics, Sysmex, Tosoh
Yahoo Finance
- Macro2026-05-17
Solid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen’s Large-Cap Stock Picks
Yahoo Finance
Premium · Free with any account
The stock has fallen 27% in 2026 following multiple weak quarterly earnings reports, significantly underperforming the S&P 500's 27% gain over the past year [Yahoo Finance]
Risks
5
Opportunities
7
Red flags
3
Leadership
10
14 more findings in the full report — free with any account.
Unlock the full Danaher Corporation analysis
Create a free account to access the complete AI-generated report with inline citations.
- 5 risks, 7 opportunities and 3 red flags — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?